Evidence map›Paper›PMID 34870812›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Identification of Glycan-Specific Variable Lymphocyte Receptors Using Yeast Surface Display and Glycan Microarrays.

Tanya R McKitrick, Melinda S Hanes, Charles S Rosenberg, Jamie Heimburg-Molinaro, Max D Cooper, Brantley R Herrin, Richard D Cummings

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. The mannose receptor ligands and the macrophage glycome.Current opinion in structural biology · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tanya R McKitrickDepartment of Surgery, Beth Israel Deaconess Medical Center, National Center for Functional Glycomics, Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA, USA.
Melinda S HanesDepartment of Surgery, Beth Israel Deaconess Medical Center, National Center for Functional Glycomics, Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA, USA.
Charles S RosenbergDepartment of Pathology and Laboratory Medicine, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
Jamie Heimburg-MolinaroDepartment of Surgery, Beth Israel Deaconess Medical Center, National Center for Functional Glycomics, Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA, USA.
Max D CooperDepartment of Pathology and Laboratory Medicine, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
Brantley R HerrinMolecular and Cell Biology at Acceleron Pharma, Cambridge, MA, USA.
Richard D CummingsDepartment of Surgery, Beth Israel Deaconess Medical Center, National Center for Functional Glycomics, Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA, USA. rcummin1@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USEmory University · USHarvard University · USAcceleron Pharma (United States) · US

Funding

Characterization of the Lamprey Adaptive Immune SystemR01AI072435 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Max Dale Cooper · 2007 to 2026
$8.1M
Overall Priority Score P41GM103694 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D · 2013 to 2018
$6.9M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
Smart Anti-Glycan Reagents to Generate the Human Glycome Atlas-SupplementU01CA199882 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D, MERNAUGH, RAYMOND L · 2015 to 2017
$2.0M
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey SystemR01GM140201 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D · 2021 to 2023
$1.5M
NCI NIH HHS U01 CA199882NIAID NIH HHS R01 AI072435NIAID NIH HHS T32 AI074492NIGMS NIH HHS P41 GM103694NIGMS NIH HHS R01 GM140201
6 · The paper itself

Abstract

The jawless vertebrates (lamprey and hagfish) evolved a novel adaptive immune system with many similarities to that found in the jawed vertebrates, including the production of antigen-specific circulating antibodies in response to immunization. However, the jawless vertebrates use leucine-rich repeat (LRR)-based antigen receptors termed variable lymphocyte receptors (VLRs) for immune recognition, instead of immunoglobulin (Ig)-based receptors. VLR genes are assembled in developing lymphocytes through a gene conversion-like process, in which hundreds of LRR gene segments are randomly selected as template donors to generate a large repertoire of distinct antigen receptors, similar to that found within the mammalian adaptive immune system. Here we describe the development of a robust platform using immunized lampreys (Petromyzon marinus) for generating libraries of anti-carbohydrate (anti-glycan) variable lymphocyte receptor B, or VLRBs. The anti-carbohydrate VLRBs are isolated using a yeast surface display (YSD) expression platform and enriched by binding to glycan microarrays through the anti-glycan VLRB. This enables both the initial identification and enrichment of individual yeast clones against hundreds of glycans simultaneously. Through this enrichment strategy a broad array of glycan-specific VLRs can be isolated from the YSD library. Subsequently, the bound yeast cells are directly removed from the microarray, the VLR antibody clone is sequenced, and the end product is expressed as a VLR-IgG-Fc fusion protein that can be used for ELISA, Western blotting, flow cytometry, and immunomicroscopy. Thus, by combining yeast surface display with glycan microarray technology, we have developed a rapid, efficient, and novel method for generating chimeric VLR-IgG-Fc proteins that recognize a broad array of unique glycan structures with exquisite specificity.

Indexed as

LampreysSaccharomyces cerevisiaeAnimalsImmunoglobulin GLymphocytesPetromyzonPolysaccharidesReceptors, AntigenVertebratesImmunoglobulin GPolysaccharidesReceptors, AntigenAnti-glycan reagentsGlycanLampreyPetromyzon marinusVariable lymphocyte receptorsVLRBYeast surface display

Identifiers

PMID34870812
PMCPMC9307140
OpenAlexW4200289201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.